identified potential therapeutic options related to relevant signaling pathways for the treatment of dopamine-resistant prolactinomas, highlighting the JAK/STAT3, PI3K-Akt-mTOR, MAPK/AMPK, and JAK2/STAT5 pathways. This evidence concerns the gene AKT1 and prolactin-producing pituitary gland adenoma.